Login to Your Account

PsiOxus Lands $34M to Create 4 Years of Runway for ColoAd1

By Nuala Moran
Staff Writer

Tuesday, July 10, 2012
LONDON – PsiOxus Therapeutics Ltd. has raised £22 million (US$34 million) in its Series B round to finance the first clinical trial of its systemically acting oncolytic virus ColoAd1, in a 132-patient colorectal cancer study that will get under way in September.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription